Gurnet Point Capital

Ms. Seltzer joined Gurnet Point Capital in 2022 and serves as a Partner. She also currently serves on the board of Reneo Pharmaceuticals, a NASDAQ listed biotechnology company. Previously, Ms. Seltzer was a Partner at Aisling Capital, a life sciences investment firm. There, her prior board service included Agile Therapeutics, Aimmune Therapeutics (acquired by Nestle Health Sciences), AVROBIO, Durata Therapeutics (acquired by Actavis), Miramar Labs (acquired by Sientra), Prolacta Bioscience, Promentis Pharmaceuticals, Spruce Biosciences, Wugen and ZELTIQ Aesthetics (acquired by Allergan). Ms. Seltzer serves on the Life Science Council for Springboard Enterprises, the Investment Advisory Board of the Blavatnik Fund for Innovation at Yale, and the Yale School of Management Advisory Board.

Prior to Aisling, Ms. Seltzer was at Schering-Plough, where she held roles in business development, marketing and sales, most recently serving at U.S. Schering-Plough as Brand Lead for Zetia. While in business development, Ms. Seltzer was involved in the structuring and negotiation of several deals with an aggregate value in the billions, ranging from in-licensing deals to broad development and commercialization alliances. Prior to Schering-Plough, Ms. Seltzer was the Director of Business Development for Akceli, a biotechnology company developing cell-based microarrays. Ms. Seltzer began her career as a management consultant for McKinsey & Company.

Ms. Seltzer received her M.B.A. from The Wharton School at the University of Pennsylvania, where she was a Palmer Scholar, and her M.S. and B.S. in Molecular Biophysics and Biochemistry from Yale University, awarded cum laude.